News
03-10-2010, 11:21 PM
Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy.
More... (http://www.news-medical.net/news/20100311/Cytokeratins-8-and-18-can-strongly-enhance-breast-cancer-drug-fulvestrants-anti-estrogenic-activity.aspx)
More... (http://www.news-medical.net/news/20100311/Cytokeratins-8-and-18-can-strongly-enhance-breast-cancer-drug-fulvestrants-anti-estrogenic-activity.aspx)